Table 1. Studies comparing denosumab vs zoledronic acid.
Column 1 | Column 2 | Column 3 |
Type of study | Author | Results |
RCT | Lipton et al. | Delay in first SRE (HR 0.82, CI 0.71-0.95,p =0.01), median time: unknown in denosumab vs 26.4 months in zoledronic acid [7]. |
RCT | Fizazi et al. | Delay in first SRE (HR 0.82, CI 0.71-0.95, p<=0.01), median time: 20.7 months in denosumab vs 17.1 months in zoledronic acid [8]. |
meta-analysis | Chen C et al. | Delay in first SRE (HR = 0.86; 95% CI, 0.80–0.93; P = 0.0001), no difference in overall survival [9]. |
meta-analysis | Zheng G et al. | Delay in first SRE (OR =0.82; 95% CI, 0.75-0.89; P < 0.01), no difference in overall survival [10]. |
meta-analysis | Hayes et al. | Delay onset of bone metastasis in non-metastatic prostate cancer (RR 0.83, CI 0.73-0.95; P <0.01) [11]. |